医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EOS imaging: First EOSedge™ Installation in Australia

2020年10月13日 PM02:10
このエントリーをはてなブックマークに追加


 

PARIS

EOS imaging (Euronext, FR0011191766 – EOSI – PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, announces the first EOSedge™ system installation in Australia at Macquarie University Hospital. Australia has 23 EOS systems installed, making this the first installation in the country of its new EOSedge system.

Opened in 2010, Macquarie University Hospital offers a new era in Australian healthcare and is recognized worldwide for research, teaching and a focus on excellent patient care.

“The safety and comfort of our patients is at the center of everything we do. We are constantly seeking the most advanced technologies in order to provide innovative and outstanding treatment. EOSedge is the right choice to support our clinicians and it fits with our strategy of delivering exceptional care at all stages, such as diagnosis, treatment planning and follow-up.” says Walter Kmet, CEO of Macquarie University hospital.

In line with the Company’s dedication to informed diagnostic imaging, EOSedge captures low dose full body biplanar exams in a weight-bearing position, providing undistorted images and precise anatomical measurements of patients in functional positions to guide treatment. With a high-resolution photon counting detector, EOSedge is the first general X-ray system offering this detection technology worldwide. The EOSedge system’s open cabin design, which includes a motorized patient platform, provides a large field of view that supports technologists with patient positioning, while also providing patients with a comfortable experience.

Mike Lobinsky, CEO of EOS imaging, comments: “EOS imaging continues to forge partnerships with leading institutions around the world and we are proud to see Macquarie University Hospital implement EOSedge in their facility. This first installation in Australia reveals the speed and scale of our global commercial introduction. After Europe and North America, Australia leads the expansion of EOSedge into the Asia-Pacific region”.

ABOUT EOS imaging

EOS imaging is a global medical device company that designs, develops and markets innovative, low dose 2D/3D full body and weight-bearing imaging, rapid 3D modeling of EOS patient X-ray images, web-based patient-specific surgical planning, and integration of surgical plan into the operating room, that collectively bridge the entire spectrum of care from imaging to post-operative assessment capabilities for orthopedic surgery. With a primary focus on hips, knees, and spine, EOS imaging is targeting a $2 billion annual market opportunity. EOS imaging has over 350 system installations in more than 40 countries generating more than 1 million patient exams annually. EOS imaging has 23 EOS systems installed in Australia and is represented by Surgicom Pty Ltd in Australia and New Zealand.

EOS imaging has corporate locations in U.S., France, Canada, Germany, and Singapore, and has more than 165 employees.

For additional information, please visit www.eos-imaging.com.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005883/en/

CONTACT

EOS imaging

Valérie Worrall

CFO

investors@eos-imaging.com

(+33) 1 55 25 60 60

FP2COM

Press Relations

Florence Portejoie

fportejoie@fp2com.fr

(+33) 6 07 76 82 83

NewCap

Investor Relations

Thomas Grojean

eos-imaging@newcap.eu

(+33) 1 44 71 94 94

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024